Loss of calcium (Ca 2+ ) homeostasis contributes through different mechanisms to cell death occurring during the first minutes of reperfusion. One of them is an unregulated activation of a variety of Ca 2+ -dependent enzymes, including the non-lysosomal cysteine proteases known as calpains. This review analyses the involvement of the calpain family in reperfusion-induced cardiomyocyte death. Calpains remain inactive before reperfusion due to the acidic pHi and increased ionic strength in the ischaemic myocardium. However, inappropriate calpain activation occurs during myocardial reperfusion, and subsequent proteolysis of a wide variety of proteins contributes to the development of contractile dysfunction and necrotic cell death by different mechanisms, including increased membrane fragility, further impairment of Na + and Ca 2+ handling, and mitochondrial dysfunction. Recent studies demonstrating that calpain inhibition contributes to the cardioprotective effects of preconditioning and postconditioning, and the beneficial effects obtained with new and more selective calpain inhibitors added at the onset of reperfusion, point to the potential cardioprotective value of therapeutic strategies designed to prevent calpain activation.
Introduction
Calpains form a large family of non-lysosomal neutral cysteine proteases that require Ca 2+ for activity. Tightly regulated by their endogenous inhibitor calpastatin, calpains participate in Ca 2+ -regulated processes such as cell proliferation and differentiation, migration, signal transduction, and platelet activation. However, deregulated calpain activity has been associated with a variety of pathophysiological conditions which have in common the loss of intracellular Ca 2+ control. 1 A large amount of experimental data demonstrate that alteration in cellular Ca 2+ homeostasis plays a central role in the processes leading to reperfusion-induced cell death, and many studies have identified different potential therapeutic targets directed at Ca 2+ overload during reperfusion and its consequences. 2 Among the mechanisms of Ca 2+ -mediated injury, the activation of different enzymes, and in particular of calpains, has been demonstrated to contribute to myocardial cell death by different mechanisms. In this review, we will briefly describe the events leading to Ca 2+ overload during myocardial ischaemia/reperfusion and then summarize the process of calpain activation, the available data supporting their contribution to cell death, and the mechanisms by which calpains mediate this injury. Finally, we will provide evidence supporting the value of calpain inhibition as a cardioprotective therapy.
2. Ischaemia/reperfusion-mediated Ca 21 overload
Regulation of Ca 2+ handling is an active cellular process that requires a large energy expenditure. The measurement of Ca 2+ kinetics, either in isolated cardiomyocytes 3, 4 or in isolated perfused hearts, 5, 6 demonstrates that energy depletion during ischaemia results in a sustained rise in intracellular Ca 2+ concentration, largely mediated by the Ca 2+ influx through the reverse mode of sarcolemmal Na + /Ca 2+ exchanger (NCX). 7 -11 The direction of NCX operation depends on the difference between transmembrane potential and the reversal potential which is determined by the intra-and extracellular concentrations of Na + and Ca 2+ . 7 During ischaemia, a net Ca 2+ influx through reverse NCX transport is predicted due to membrane depolarization and reduced Na + gradient. The latter is a consequence of Na + i rise attributed to the inhibition of Na + /K + -ATPase and to an increased Na + -influx associated with the activation of proton extrusion mechanisms like Na + /H + exchanger and Na + /HCO 3 -cotransporter, 12,13 as well as to persistent (non-inactivating) Na + channels. The activity of CaMKII is increased during ischaemia/reperfusion and its inhibition reduces cell death. 20 It has been suggested that CaMKII accelerates the rate of pHi recovery at the onset of reperfusion by phosphorylation of the C-terminal domain of Na + /H + exchanger.
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This effect modulates Ca 2+ entry into the cell but also activates mechanisms involved in reperfusion injury that are repressed by low pHi. 22 
Calpain activation during ischaemia/reperfusion
The most abundant calpain isoforms, m-calpain and m-calpain, are expressed in the heart. 23 -25 28, 29 In agreement with this model, the activation of calpains has been observed in isolated cardiomyocytes with a moderate increase in Ca 2+ concentration ( 500 nM), 30 much lower than the concentration reached during ischaemia. 31 -33 The determination of calpain activity by assessing the proteolysis of known calpain substrates in tissue homogenates or of synthetic peptides in intact cells consistently confirms that calpains are activated during ischaemia/reperfusion. 34 -40 However, the main isoform responsible for the observed proteolytic activity has not yet been elucidated as there are no isoform-specific inhibitors available 41 and no genetic approaches have been used for this purpose.
Kinetics of activation
Until recently, the kinetics of calpain activation during ischaemia/ reperfusion and the contribution of the different factors that regulate calpain activity were poorly defined. While in some studies, the activity of calpains was detected in isolated cardiomyocytes submitted to hypoxia or metabolic inhibition without reoxygenation, 42, 43 early studies performed in the intact heart did not observe proteolytic activity during myocardial ischaemia. 35, 44 Since low pHi inhibits calpains in vitro, 45, 46 the absence of a significant intracellular acidosis in the cell models compared with the intact heart could explain these discrepancies. In agreement with this notion, recently our group has demonstrated that during ischaemia Ca 2+ overload induces the translocation of m-calpain to the sarcolemma, but ischaemic acidosis prevents the enzyme activation. Calpain activation occurs exclusively during reperfusion, after pHi normalization ( Figure 1 ). 
Translocation to the sarcolemma
Whether the calpain translocation process that already occurs during ischaemia is a necessary step for its activation during reperfusion is relevant as it could generate an irreversible preactivation state, only transiently blocked by ischaemic intracellular acidosis. However, in a recent study, a reduction in the calpain fraction bound to the membranes by the disruption of lipid rafts demonstrated that calpain translocation during ischaemia is not mandatory for its activation at reperfusion. 40 These results are in accordance with those obtained in other pathological models 47, 48 and in contrast with the studies that analyse calpain activation under physiological conditions and suggest that in those situations leading to severe Ca 2+ overload as occurs during ischaemia, calpain translocation is not a necessary step for their activation.
Calpain phosphorylation
Calpains have been reported to present several residues phosphorylated under physiological conditions. 49 Some residues can be specifically phosphorylated by kinases such as protein kinase A (PKA), which inhibits m-calpain activity, 50 or extracellular signal-regulated kinases, which can activate m-calpain even in the absence of an increase in the Ca 2+ concentration, 51 and CaMKII. 52 Although the involvement of these kinases in the mechanisms of ischaemia/reperfusion injury and cardioprotection has been largely reported in the bibliography, 53 the regulation of calpain activity by phosphorylation during ischaemia/ reperfusion has not been analysed. Only a relation between PKA activity during ischaemic preconditioning and inhibition of calpain activity after ischaemia/reperfusion has been described, although no clues about the nature of this interaction were given. 38 
Calpastatin
The ubiquitous calpains, m and m, have a specific endogenous inhibitor, calpastatin, which is also expressed in the heart. 40,54 -59 The proposed role for calpastatin is to prevent excessive activation of calpains in the case of increased Ca 2+ concentration. However, calpastatin has been shown to be largely down-regulated during reperfusion due to the proteolytic activity of calpains 40, 58 or the proteasome. 60 Research in other possible mechanisms regulating calpain/calpastatin interaction, such as Ca 2+ concentration, calpastatin phosphorylation, or translocation to membrane, is scarce in the heart and absent for ischaemia/reperfusion.
56,57,59
Modifications related to oxidative stress
It is well accepted that a burst of oxygen free radicals is generated during the first minutes of reperfusion and several works have demonstrated that oxidative stress can modify the activity of calpains, although the overall effect of free radicals on calpain activity during myocardial reperfusion is unclear. On the one hand, S-nitrosylation can inhibit calpain activity in vitro and in neutrophils in a pH-dependent way, 61, 62 and it has also been suggested to regulate calpain activity in the reperfused heart. In agreement with these studies, L-arginine administration before and after ischaemia without preventing the formation of oxygen free radicals reduced calpain activity while augmenting their nitrosylation. 63 On the other hand, carbonylation has been shown to increase substrate susceptibility to calpain-dependent proteolysis in neurons and other cellular types, but the importance of this modification has not been studied in myocardial tissue nor in ischaemia/reperfusion. 64, 65 Ischaemia/reperfusion has been shown to increase protein nitrosylation 66 and carbonylation 67 and that Snitrosylation has been implied in cardioprotection. 68, 69 Whether or not these post-translational modifications of calpains are relevant regulatory mechanisms compared with the activation induced by an excessive Ca 2+ overload during reperfusion deserves further study.
Contribution of calpains to ischaemia/reperfusion injury
The use of calpain inhibitors 35, 37, 38, 40, 44, 70, 71 and transgenic models overexpressing calpastatin 72, 73 by several groups in different models of ischaemia/reperfusion have consistently demonstrated that calpain activation plays an important role in reperfusion-induced contractile dysfunction and cell death due to the proteolysis of a wide variety of proteins ( Figure 2 ). Several mechanisms have been proposed by which calpains may contribute to reperfusion injury ( Figure 3 ).
Increased sarcolemmal fragility
Studies showing reduced tolerance of cardiomyocytes to osmotic stress demonstrate that ischaemia/reperfusion increases the fragility of the sarcolemma. 74 , 75 Sarcolemmal fragility has been shown to Figure 1 Calpain activation during myocardial ischaemia and reperfusion. Western blots show m-calpain translocation to the membranes and calpain activation (145/150 kDa calpain-dependent cleavage fragments of a-fodrin) after ischaemia with or without reperfusion in the isolated rat heart. 60MDL: hearts were perfused with the calpain inhibitor MDL-28170 before 60 min of ischaemia. Reperfusion lasted 15 min. Results are expressed in percentage with respect to normoxically perfused hearts (Nx ¼ 0) and demonstrate that calpain translocates to the membrane during ischaemia but activates during reperfusion. Modified from Hernando et al. 40 with permission from Elsevier.
play an important role in sarcolemmal rupture occurring during the initial minutes of reperfusion by reducing the cell tolerance to the mechanical stress generated by the development of hypercontracture and cell swelling. 74, 76 It has been proposed that the sarcolemmal weakening during ischaemia/reperfusion is a consequence of an altered lipidic composition 77 and the degradation of structural proteins. 78 Although the mechanisms underlying these alterations remain incompletely defined, evidence indicates that the proteolytic activity of calpains plays a critical role in cell fragility, mainly through the cleavage of a-fodrin. a-Fodrin forms the backbone of the membrane cytoskeleton, and its degradation during ischaemia/reperfusion has been shown to correlate linearly with increased membrane fragility. 75 It is well established that the uncontrolled activation of calpains leads to the degradation of fodrin 79 into two fragments of 150 and 145 kDa and, in fact, this specific pattern of cleavage is widely used as an index of calpain activity. 80 Other calpain substrates whose proteolysis could contribute to increase cell fragility are the subsarcolemmal dystrophin 81 and the cytoskeleton-associated proteins paxillin, vinculin, and talin which locate within the focal adhesion complex and mediate the anchorage of the plasma membrane to the cytoskeleton. 82 
Impairment of Ca 21 handling
Once activated, calpains may also contribute to further impairment of Ca 2+ handling occurring during reperfusion through different mechanisms. The sarcolemmal protein ankyrin has a central domain that binds to a-fodrin and an N-terminal domain that interacts with several receptors and channels including the a-subunit of Na + /K + -ATPase. 83 Binding to ankyrin connects the Na + /K + -ATPase to the fodrin-based membrane cytoskeleton and determines its specific location in the sarcolemma and its correct function. 84 During reperfusion, it has been demonstrated that calpains proteolyse both fodrin and ankyrin producing the detachment of the a-subunit of the Na 
Mitochondria
The effects of calpains on mitochondria are the subject of a review included in this issue. It has been proposed that calpain activation during myocardial ischaemia/reperfusion is responsible for initiating a mitochondrial-dependent apoptotic programme independent of caspases 91 that is related to the calpain-dependent activation of Bid. 92, 93 In addition, although considered cytoplasmic enzymes, recent studies suggest the existence of different calpain isoforms in the mitochondria. 94, 95 The activation of mitochondrial calpains during reperfusion has been proposed to be responsible of the degradation of the mitochondrial inner membrane NCX 87 and the activation of apoptosis-inducing factor. 71 
Degradation of myofibrillar proteins
Calpain-dependent degradation of proteins involved in the contractile machinery has been involved in post-ischaemic myocardial dysfunction. Analysis of in vitro protein degradation by m-calpain in human myocardial tissue samples demonstrated that the myofibrillar proteins titin, desmin, cTnT, and cTnI are calpain substrates, suggesting that the uncontrolled intracellular activation of calpains alters the structure and the regulation of the contractile machinery in the human heart in vivo. 96 It has been demonstrated that overexpression of calpastatin induced by gene transfer prevents cTnI degradation and ameliorates contractile dysfunction in rat hearts subjected to ischaemia/reperfusion. 73 Another troponin, cTnT, has been shown to be truncated by calpains after ischaemia/reperfusion and the transgenic expression of this truncated cTnT changed the kinetics of myocardial contraction in healthy hearts. 97, 98 In addition to troponin, the cleavage of desmin by calpains detected in reperfused hearts 38,44,99,100 was proposed to contribute to cardiac dysfunction. 44, 99 The overexpression of Hsp27 has been shown to improve post-ischaemic contractile function by reducing the interaction between m-calpain, cTnI, cTnT, and desmin during ischaemia/reperfusion. 100,101
Proteolysis of regulatory enzymes
Through the proteolysis of regulatory enzymes, calpains may contribute indirectly to reperfusion injury by altering different signalling pathways. Calpain-mediated degradation of protein kinase C (PKC) into protein kinase M was described years ago, 102 and recently, it has been demonstrated that the proteolytic processing of PKCa by calpains activates pathological cardiac signalling through the generation of a C-terminal fragment with unregulated kinase properties. 103 Calcineurin and CaMKII have been proposed to be both activators and substrates of calpains. Calcineurin, by increasing cytosolic Ca 2+ concentration through the inhibition of SERCA, 19 and CaMKII by accelerating pHi recovery at the onset of reperfusion through the phosphorylation of the Na + /H + exchanger 21 may favour calpain activation.
The 60 kDa subunit of calcineurin has been identified as a calpain substrate, 104 and its calpain-mediated proteolysis has been suggested to increase its phosphatase activity in reperfused rat hearts and the human ischaemic myocardium. 105 Studies in vitro demonstrate the proteolysis of CaMKs by calpains. 106 It has been shown the existence of a nuclear m-calpain acting as a regulator of CaMKIV and associated signalling molecules under conditions of sustained Ca 2+ influx in neurons. 107 In addition, neuronal CaMKII is proteolysed and activated by calpains. 108, 109 However, although these enzymes have important roles in different signalling pathways, the effect of their calpaindependent cleavage on reperfusion injury remains unknown.
Calpain inhibition

Pharmacological inhibition of calpains during ischaemia/reperfusion
Many studies have evaluated the effectiveness of calpain inhibition as cardioprotective therapy against myocardial reperfusion injury ( Table 1) . These studies have been performed in both in vivo and ex vivo experimental models and using diverse inhibitors which differ in their pharmacological characteristics. Leupeptin was the first drug used as calpain inhibitor in the context of ischaemia/reperfusion. However, although leupeptin preserved contractile function in isolated guinea pig hearts subjected to transient ischaemia, 110 this drug inhibits other proteases like cathepsins, plasmin, or trypsin.
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N-Ac-Leu-Leu-norleucinal (ALLN or calpain inhibitor I), a derivative from leupeptin, and MDL-28170 (calpain inhibitor III), although more specific for calpains, may also inhibit cathepsins. 111 They have been used in several studies, most of them in isolated hearts, and demonstrated protective effects against reperfusion-induced cell death and contractile dysfunction. 37, 112, 113 However, a problem shared by these inhibitors that limits their applicability in vivo is their poor aqueous solubility. More recently, new water-soluble and cellpermeable calpain inhibitors were tested. Among them, A-705239 and A-790523 reduced infarct size in isolated rabbit hearts 70 and in an in vivo pig model of ischaemia/reperfusion, 114 and SNJ-1945 preserved contractile function in hearts submitted to cardioplegia. 40 Although calpains are activated after pHi correction during early reperfusion, 40, 113 in most of these studies, the drug was administered before ischaemia. Only two studies, using A-705253 and MDL-28170, have demonstrated the cardioprotective potential of calpain inhibitors when administered at the onset of reperfusion in ex vivo and in vivo models. 115 While the beneficial effects of calpain inhibition in the context of acute reperfusion injury are well supported, the consequences of prolonged calpain inhibition are less clear. Recently, chronic m-calpain inhibition has been associated with the development of dilated cardiomyopathy due to the abnormal accumulation of protein aggregates, suggesting that m-calpain is necessary for ubiquitination and proteasomal-dependent degradation. 38, 92, 116 These latter results highlight the importance of developing inhibitors with calpain isoform specificity.
Ischaemic preconditioning
Ischaemic preconditioning has been shown to prevent calpain activation during myocardial reperfusion in several studies. 38 The further observation that calpain inhibitors can partially reproduce the protective effects of preconditioning and that calpain activity is modified by treatments aimed to mimic or blunt the effects of preconditioning strongly suggests that calpain inhibition mediates at least in part the protection afforded by ischaemic preconditioning. 92 Although calpain inhibition by preconditioning was proposed to be consequence of reduced Ca 2+ entry during index ischaemia in hearts previously subjected to preconditioning cycles, 117 there is evidence that preconditioning prevents calpain activity by phosphorylation. Freshly isolated calpains contain several conserved consensus sites for PKA phosphorylation, 50 and it has been suggested that phosphorylation at serine 369 by PKA inhibits m-calpain. 38, 118, 119 The preconditioning phase results in transient PKA activation, and the abolition of this activation blunts the protective effects of ischaemic preconditioning, whereas these effects, including calpain inhibition, are mimicked by transient PKA stimulation. 120, 121 Whether PKA exerts its effect on calpain activity by direct phosphorylation of the proteases or by the action of other proteins related to the pathway triggered by PKA activation remains to be elucidated.
Ischaemic postconditioning
Different groups including ours have demonstrated that the effectiveness of a postconditioning protocol in limiting infarct size depends on its ability to delay normalization of intracellular acidosis during the initial minutes of reperfusion. 122 Recent results propose that protein kinase G-dependent inhibition of Na + /H + exchanger together with reduced lactate washout determine the observed delay in pH correction. 22 The prolongation of acidosis may be protective by modulating many mechanisms implicated in reperfusion injury 121 and we have recently shown that slowing pH recovery during reperfusion by postconditioning or by acidic perfusion limits myocardial necrosis at least in part through the attenuation of calpain activation. 40 These data support recent evidence demonstrating that cal- 
Perspectives
Recent studies demonstrating that calpain activation occurs exclusively during reperfusion, and the cardioprotective effects obtained preventing their activation by either postconditioning or by using pharmacological inhibitors applied at the onset of reperfusion, demonstrate that calpain inhibition is a potentially useful therapeutic strategy aimed to limit infarct size during myocardial reperfusion. However, although calpains were pointed out as an orphan target against reperfusion injury, 124,125 translation of the use of calpain inhibitors into clinical trials has been hampered due to the lack of inhibitors with calpain isoform specificity available for human use. Recent progress made in the crystal structure of m-calpain with bound inhibitors, and the development of methods for site-specific delivery of drugs should facilitate the identification of new calpain-specific inhibitors, selective for each isoform, and reduce the potential toxicity that could result from indiscriminate calpain inhibition. Hopefully, these advancements will allow to test this promising therapeutic strategy against reperfusion injury in humans in the future. 
